Clinical trial
Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease: a Prospective, Multicenter, Real-world, Registry Study
NCT05391815 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease: a Prospective, Multicenter, Real-world, Registry Study
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 1, 2021
- Completion date
- June 1, 2032
- Enrollment
- 800 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.